Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term chemotherapy. Found 241 abstracts

paginate
Ayers EC, Li S, Medeiros LJ, Bond DA, Maddocks KJ, Torka P, Mier Hicks A, Curry M, Wagner-Johnston ND, Karmali R, Behdad A, Fakhri B, Kahl BS, Churnetski MC, Cohen JB, Reddy NM, Modi D, Ramchandren R, Howlett C, Leslie LA, Cytryn S, Diefenbach CS, Faramand R, Chavez JC, Olszewski AJ, Liu Y, Barta SK, Mukhija D, Hill BT, Ma H, Amengual JE, Nathan S, Assouline SE, Orellana-Noia VM, Portell CA, Chandar A, David KA, Giri A, Hess BT, Landsburg DJ. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer. 2020 Jan 15;126(2):293-303.
Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Chih-Hsin Yang J, Gubens M, Sequist LV, Awad MM, Fiore J, Saraf S, Keller SM, Gandhi L. 24-Month Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab As First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Thorac Oncol. 2019 Jan;14(1):124-9.
Gockley A, Melamed A, Cronin A, Bookman MA, Burger RA, Cristae MC, Griggs JJ, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland J, O'Malley DM, Wright AA. Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer. American journal of obstetrics and gynecology. 2019 Jun 14;.
Gockley A, Melamed A, Cronin A, Bookman MA, Burger RA, Cristae MC, Griggs JJ, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland J, O'Malley DM, Wright AA. Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer. American journal of obstetrics and gynecology. 2019 Dec;221(6):625e1-625e14.
Stinchcombe TE, Fan W, Schild SE, Vokes EE, Bogart J, Le QT, Thomas CR, Edelman MJ, Horn L, Komaki R, Cohen HJ, Kishor Ganti A, Pang H, Wang X. A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. Cancer. 2019 Feb;125(3):382-90.   PMCID: PMC6340765
Voss MH, Bhatt RS, Vogelzang NJ, Fishman M, Alter RS, Rini BI, Beck JT, Joshi M, Hauke R, Atkins MB, Burgess E, Logan TF, Shaffer D, Parikh R, Moazzam N, Zhang X, Glasser C, Sherman ML, Plimack ER. A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma. Cancer. 2019 Apr 05;125(14):2400-8.   PMCID: PMC6602847
Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S, Agarwal N, Yu EY, Niegisch G, Necchi A, Sternberg CN, Srinivas S, Alva A, Vaishampayan U, Cerbone L, Liontos M, Rosenberg J, Powles T, Belmunt J, Galsky MD, Risc Investigators. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: A Retrospective International Study of Invasive/advanced cancer of the urothelium (RISC). Ann Oncol. 2018 Feb;29(2):361-9.
Fareed MM, DeMora L, Esnaola NF, Denlinger CS, Karachristos A, Ross EE, Hoffman J, Meyer JE. Concurrent chemoradiation for resected gall bladder cancers and cholangiocarcinomas. Journal of gastrointestinal oncology. 2018 Aug;9(4):762-8.   PMCID: PMC6087856
Garriga J, Laumet G, Chen SR, Zhang Y, Madzo J, Issa JJ, Pan HL, Jelinek J. Nerve injury-induced chronic pain is associated with persistent DNA methylation reprogramming in dorsal root ganglion. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2018 Jul 04;38(27):6090-101.   PMCID: PMC6031579
Garriga J, Laumet G, Chen SR, Zhang Y, Madzo J, Issa JJ, Pan HL, Jelinek J. Nerve Injury-Induced Chronic Pain Is Associated with Persistent DNA Methylation Reprogramming in Dorsal Root Ganglion. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2018 Jul 04;38(27):6090-101.   PMCID: PMC6031579
Ghatalia P, Zibelman M, Geynisman DM, Plimack E. Approved checkpoint inhibitors in bladder cancer: which drug should be used when?. Therapeutic advances in medical oncology. 2018 Jul;10:1758835918788310.   PMCID: PMC6066800
Stinchcombe TE, Fan W, Schild SE, Vokes EE, Bogart J, Le QT, Thomas CR, Edelman MJ, Horn L, Komaki R, Cohen HJ, Kishor Ganti A, Pang H, Wang X. A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. Cancer. 2018 Oct 21;.
Tan CR, Barta SK, Lee J, Rudek MA, Sparano JA, Noy A. Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034. Leukemia & lymphoma. 2018 Aug;59(8):1851-60.   PMCID: PMC5962410
De Bari B, Stish B, Ball MW, Habboush Y, Sargos P, Krengli M, Bossi A, Stabile A, Sole Pesutic C, Lestrade L, Smeenk RJ, Jereczek-Fossa BA, Zilli T, Crehange G, Alongi F, Zaorsky N, Ozsahin M. Adult prostatic sarcoma: A contemporary multicenter Rare Cancer Network study. The Prostate. 2017 Jul;77(10):1160-6.
Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CA, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. Cancer. 2017 Jul;123(13):2489-96.   PMCID: PMC5474197
Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CA, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. Cancer. 2017 Mar 21;.
Jackson-Rose J, Del Monte J, Groman A, Dial LS, Atwell L, Graham J, O'Neil Semler R, O'Sullivan M, Truini-Pittman L, Cunningham TA, Roman-Fischetti L, Costantinou E, Rimkus C, Banavage AJ, Dietz B, Colussi CJ, Catania K, Wasko M, Schreffler KA, West C, Siefert ML, Rice RD. Chemotherapy Extravasation: Establishing a National Benchmark for Incidence Among Cancer Centers. Clinical journal of oncology nursing. 2017 Aug;21(4):438-45.
Mirkin KA, Hollenbeak CS, Mohamed A, Jia Y, El-Deiry WS, Messaris E. Impact of perineural invasion on survival in node negative colon cancer. Cancer Biol Ther. 2017 Sep 02;18(9):740-5.   PMCID: PMC5663408
Ramos JD, Casey MF, Bamias A, De Giorgi U, Bellmunt J, Harshman LC, Ladoire S, Wong YN, Alva AS, Rosenberg JE, Galsky MD, Yu EY, Retrospective International Study of Cancers of the Urothelium I. The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy. Clin Appl Thromb Hemost. 2017 Oct;23(7):755-60.
Schuetze SM, Bolejack V, Choy E, Ganjoo KN, Staddon AP, Chow WA, Tawbi HA, Samuels BL, Patel SR, von Mehren M, D'Amato G, Leu KM, Loeb DM, Forscher CA, Milhem MM, Rushing DA, Lucas DR, Chugh R, Reinke DK, Baker LH. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. Cancer. 2017 Jan;123(1):90-7.
Esnaola NF, Meyer JE, Karachristos A, Maranki JL, Camp ER, Denlinger CS. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer. 2016 May;122(9):1349-69.
Esnaola NF, Meyer JE, Karachristos A, Maranki JL, Camp ER, Denlinger CS. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer. 2016 May;122(9):1349-69.
Rice TW, Lerut TE, Orringer MB, Chen LQ, Hofstetter WL, Smithers BM, Rusch VW, van Lanschot J, Chen KN, Davies AR, D'Journo XB, Kesler KA, Luketich JD, Ferguson MK, Rasanen JV, van Hillegersberg R, Fang W, Durand L, Allum WH, Cecconello I, Cerfolio RJ, Pera M, Griffin SM, Burger R, Liu JF, Allen MS, Law S, Watson TJ, Darling GE, Scott WJ, Duranceau A, Denlinger CE, Schipper PH, Ishwaran H, Apperson-Hansen C, DiPaola LM, Semple ME, Blackstone EH. Worldwide Esophageal Cancer Collaboration: neoadjuvant pathologic staging data. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus. 2016 Oct;29(7):715-23.
Till BG, Li H, Bernstein SH, Fisher RI, Burack WR, Rimsza LM, Floyd JD, DaSilva MA, Moore DF, Pozdnyakova O, Smith SM, LeBlanc M, Friedberg JW. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol. 2016 Oct 22;172(2):208-18.   PMCID: PMC4710555
Wang HH, Zaorsky NG, Meng MB, Wu ZQ, Zeng XL, Jiang B, Jiang C, Zhao LJ, Yuan ZY, Wang P. Multimodality therapy is recommended for limited-stage combined small cell esophageal carcinoma. Onco Targets Ther. 2015 Jan;8:437-44.   PMCID: Pmc4335610
Zhang Y, Wang J, Xie J, Yang D, Han G, Zhang Y, Fu Q. The assay and clinical significance of serum thymidine kinase 1 in patients with colorectal carcinoma. Eur Surg. 2015 Oct;47(5):248-53.
Zhao YZ, Chen LJ, Lin Q, Cai J, Yu WZ, Zhao YP, Xu CY, Mao KL, Tian FR, Li WF, Wong HL, Lu CT. Using FUS induced BBB/BTB-opening technique combined with Doxorubicin liposomes to improve glioma-targeted inhibition. Oncotarget. 2015 Sep 02;.
Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G. Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer. 2014 Apr;12(2):130-7.   PMCID: Pmc4142680
Twelves C, Chmielowska E, Havel L, Popat S, Swieboda-Sadlej A, Sawrycki P, Bycott P, Ingrosso A, Kim S, Williams JA, Chen C, Olszanski AJ, de Besi P, Schiller JH. Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Ann Oncol. 2014 Jan;25(1):132-8.   PMCID: No NIH funds
Berger AC, Winter K, Hoffman JP, Regine WF, Abrams RA, Safran H, Freedman GM, Benson AB, MacDonald J, Willett CG. Five Year Results of US Intergroup/RTOG 9704 With Postoperative CA 19-9 <= 90 U/mL and Comparison to the CONKO-001 Trial. International Journal of Radiation Oncology Biology Physics. 2012 Nov;84(3):E291-E297.
Berger AC, Winter K, Hoffman JP, Regine WF, Abrams RA, Safran H, Freedman GM, Benson AB, MacDonald J, Willett CG. Five Year Results of US Intergroup/RTOG 9704 With Postoperative CA 19-9 <= 90 U/mL and Comparison to the CONKO-001 Trial. International Journal of Radiation Oncology Biology Physics. 2012 Nov;84(3):E291-E297.
Chen JJ, Sun YL, Tiwari AK, Xiao ZJ, Sodani K, Yang DH, Vispute SG, Jiang WQ, Chen SD, Chen ZS. PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter. Cancer Science. 2012 Aug;103(8):1531-7.   PMCID: PMC3407321[Available on 2013/8/1]
Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. Gynecologic Oncology. 2012 Dec;127(3):538-43.   PMCID: PMC3568489
Colt DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dilawari RA, DiMaio D, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM. Melanoma. Journal of the National Comprehensive Cancer Network. 2012 Mar;10(3):366-400.   PMCID: not NIH funded
Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pinder-Schenck M, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC. Malignant Pleural Mesothelioma. Journal of the National Comprehensive Cancer Network. 2012 Jan;10(1):26-41.   PMCID: not NIH funded
Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Hague S, Pfister DG. A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m(2) for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer. Journal of the National Comprehensive Cancer Network. 2012 Nov;10(11):1391-8.   PMCID: no NIH
Gillet JP, Calcagno AM, Varma S, Davidson B, Elstrand MB, Ganapathi R, Kamat AA, Sood AK, Ambudkar SV, Seiden MV, Rueda BR, Gottesman MM. Multidrug Resistance-Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma. Clinical Cancer Research. 2012 Jun;18(11):3197-206.   PMCID: PMC3376649
Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Annals of Oncology. 2012 May;23(5):1144-50.   PMCID: *
Hayashi N, Nakamura S, Tokuda Y, Shimoda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. International Journal of Clinical Oncology. 2012 Apr;17(2):96-104.   PMCID: *
Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, Gilbert J, Mehra R, Moore DT, Sheikh A, Hoskins J, Hayward MC, Zhao N, O'Connor W, Weck KE, Cohen RB, Cohen EE. Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements. Clinical Cancer Research. 2012 Apr;18(7):2056-65.
Landau H, Pandit-Taskar N, Hassoun H, Cohen A, Lesokhin A, Lendvai N, Drullinsky P, Schulman P, Jhanwar S, Hoover E, Bello C, Riedel E, Nimer SD, Comenzo RL. Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease. Leukemia & lymphoma. 2012 Feb;53(2):275-81.
Makhov PB, Golovine K, Kutikov A, Teper E, Canter DJ, Simhan J, Uzzo RG, Kolenko VM. Modulation of Akt/mTOR Signaling Overcomes Sunitinib Resistance in Renal and Prostate Cancer Cells. Molecular Cancer Therapeutics. 2012 Jul;11(7):1510-7.   PMCID: PMC 3491642
Moore KN, Sill MW, Miller DS, McCourt C, De Geest K, Rose PG, Cardenes HR, Mannel RS, Farley JH, Schilder RJ, Fracasso PM. A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study. Gynecologic Oncology. 2012 Dec;127(3):456-61.   PMCID: *
Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA. Ovarian Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 Nov;10(11):1339-49.
Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB. Testicular Cancer Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2012 Apr;10(4):502-35.   PMCID: not NIH funded
Pfister DG, Ang KK, Brizel DM, Burtness B, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE. Mucosal Melanoma of the Head and Neck. Journal of the National Comprehensive Cancer Network. 2012 Mar;10(3):320-38.   PMCID: not NIH Funded
Pro B, Perini GF. Brentuximab vedotin in Hodgkin's lymphoma. Expert Opinion on Biological Therapy. 2012 Oct;12(10):1415-21.   PMCID: Not NIH Funded
Sparano JA, Goldstein LJ, Davidson NE, Sledge GW, Gray R. TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment. 2012 Jul;134(2):751-7.
Stehman FB, Brady MF, Thigpen JT, Rossi EC, Burger RA. Cytokine use and survival in the first-line treatment of ovarian cancer: A Gynecologic Oncology Group Study. Gynecologic Oncology. 2012 Dec;127(3):495-501.   PMCID: PMC3496007
Swisher SG, Winter KA, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA, Willett CG. A PHASE II STUDY OF A PACLITAXEL-BASED CHEMORADIATION REGIMEN WITH SELECTIVE SURGICAL SALVAGE FOR RESECTABLE LOCOREGIONALLY ADVANCED ESOPHAGEAL CANCER: INITIAL REPORTING OF RTOG 0246. International Journal of Radiation Oncology Biology Physics. 2012 Apr;82(5):1967-72.   PMCID: *
Wong SJ, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, Watson JC, Mitchell E, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG. RADIATION THERAPY ONCOLOGY GROUP 0247: A RANDOMIZED PHASE II STUDY OF NEOADJUVANT CAPECITABINE AND IRINOTECAN OR CAPECITABINE AND OXALIPLATIN WITH CONCURRENT RADIOTHERAPY FOR PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER. International Journal of Radiation Oncology Biology Physics. 2012 Mar;82(4):1367-75.   PMCID: PMC3208721
Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G. Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma. Journal of Clinical Oncology. 2012 Oct;30(28):3545-51.   PMCID: PMC3454772
Ajani JA, Barthel JS, Bentrem DJ, D'Amico TA, Das P, Denlinger CS, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn M, Lockhart AC, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Varghese TK, Warren G, Washington MK, Willett C, Wright CD, Meron Aj VP. Esophageal and Esophagogastric Junction Cancers. Journal of the National Comprehensive Cancer Network. 2011 Aug;9(8):830-+.   PMCID: not NIH funded
Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Huff CA, Kassim A, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F. Multiple Myeloma. Journal of the National Comprehensive Cancer Network. 2011 Oct;9(10):1146-83.   PMCID: not NIH funded
Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT, Lengyel E, Palaparthy R, Gilder K, Vassos A, McAuliffe W, Weymer S, Barton J, Schilder RJ. A phase II, single-arm study of the anti-alpha 5 beta 1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecologic Oncology. 2011 May;121(2):273-9.   PMCID: not NIH funded
Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Junck L, Linette GP, Loeffler JS, Maor MH, Michael M, Moots PL, Morrison T, Mrugala M, Nabors LB, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK, Vrionis FD, Wen PY. Central Nervous System Cancers. Journal of the National Comprehensive Cancer Network. 2011 Apr;9(4):352-400.   PMCID: not NIH funded
Carlson RW, Allred C, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Sachdev J, Smith ML, Somlo G, Ward JH, Wolff AC, Zellars R. Invasive Breast Cancer. Journal of the National Comprehensive Cancer Network. 2011 Feb;9(2):136-222.   PMCID: not NIH funded - practice guideline
Chakravarty A, Shinde V, Tabernero J, Cervantes A, Cohen RB, Dees EC, Burris H, Infante JR, Macarulla T, Elez E, Andreu J, Rodriguez-Braun E, Rosello S, von Mehren M, Meropol NJ, Langer CJ, Oneil B, Bowman D, Zhang M, Danaee H, Faron-Yowe L, Gray G, Liu H, Pappas J, Silverman L, Simpson C, Stringer B, Tirrell S, Veiby OP, Venkatakrishnan K, Galvin K, Manfredi M, Ecsedy JA. Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase. Cancer Research. 2011 Feb;71(3):675-85.   PMCID: not NIH funded
Chun YS, Cooper HS, Cohen SJ, Konski A, Burtness B, Denlinger CS, Astsaturov I, Hall MJ, Hoffman JP. Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer. Annals of Surgical Oncology. 2011 Dec;18(13):3601-7.   PMCID: not NIH funded
Crawford J, Allen J, Armitage J, Blayney DW, Cataland SR, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Steensma DP, Vadhan-Raj S, Westervelt P, Westmoreland M. Myeloid Growth Factors. Journal of the National Comprehensive Cancer Network. 2011 Aug;9(8):914-+.   PMCID: not NIH funded
Dominici L, Najita J, Hughes M, Niland J, Marcom P, Wong YN, Carter B, Javid S, Edge S, Burstein H, Golshan M. Surgery of the primary tumor does not improve survival in stage IV breast cancer. Breast Cancer Research and Treatment. 2011 Sep;129(2):459-65.   PMCID: PMC3382105
Elkin EB, Klem ML, Gonzales AM, Ishill NM, Hodgson D, Ng AK, Marks LB, Weidhaas J, Freedman GM, Miller RC, Constine LS, Myrehaug S, Yahalom J. Characteristics and Outcomes of Breast Cancer in Women With and Without a History of Radiation for Hodgkin's Lymphoma: A Multi-Institutional, Matched Cohort Study. Journal of Clinical Oncology. 2011 Jun;29(18):2466-73.   PMCID: PMC3138631[Available on 2012/6/20]
Ettinger DS, Agulnik M, Cates JM, Cristea M, Denlinger CS, Eaton KD, Fidias PM, Gierada D, Gockerman JP, Handorf CR, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Shulman LN, Smerage JB, Varadhachary GR, Zager JS, Zhen WN. Occult Primary Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2011 Dec;9(12):1358-95.   PMCID: not NIH funded
Giordano A, Giuliano M, De Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R, Hortobagyi GN, Pusztai L, De Placido S, Hess K, Cristofanilli M, Reuben JM. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. Breast Cancer Research and Treatment. 2011 Sep;129(2):451-8.   PMCID: *
Giralt SA, Mangan KF, Maziarz RT, Bubalo JS, Beveridge R, Hurd DD, Mendoza FL, Rubenstein EB, DeGroot TJ, Schuster MW. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Annals of Oncology. 2011 Apr;22(4):939-46.   PMCID: not NIH funded
Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Research. 2011 Jun;13(3):R67.   PMCID: PMC3218956
Hamilton CA, Miller A, Miller C, Krivak TC, Farley JH, Chernofsky MR, Stany MP, Rose GS, Markman M, Ozols RF, Armstrong DK, Maxwell GL. The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: A gynecologic oncology group study. Gynecologic Oncology. 2011 Sep;122(3):521-6.   PMCID: *
Hayashi N, Nakamura S, Yagata H, Shimoda Y, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series. International Journal of Clinical Oncology. 2011 Oct;16(5):596-600.   PMCID: *
Heath EI, Blumenschein GR, Cohen RB, LoRusso PM, LoConte NK, Kim ST, Ruiz-Garcia A, Chao RC, Wilding G. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemotherapy and Pharmacology. 2011 Sep;68(3):703-12.   PMCID: not NIH funded
Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow L, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan TM, Koczywas M, Moran CA, Niell HB, O'Malley J, Patel JD, Ready N, Rudin CM, Williams CC. Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network. 2011 Oct;9(10):1086-113.   PMCID: not NIH funded
Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Muller T, Ratain MJ, Salgia R. Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer. Journal of Clinical Oncology. 2011 Jul;29(19):2660-6.   PMCID: not NIH funded
Makhlin I, Zhang J, Long CJ, Devarajan K, Zhou Y, Klein-Szanto AJ, Huang M, Chernoff J, Boorjian SA. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU international. 2011 Jul;108(2B):E84-E90.   PMCID: PMC3116980
McHugh JA, Cullison S, Apuzzio J, Block JM, Cohen C, Leong SL, London WT, McNellis RJ, Neubauer RL, Perrillo R, Squires R, Tarrant D, McMahon BJ. Chronic hepatitis B infection: A workshop consensus statement and algorithm. Journal of Family Practice. 2011 Sep;60(9):E1-8.   PMCID: not NIH funded
Mego M, De Giorgi U, Dawood S, Wang XM, Valero V, Andreopoulou E, Handy B, Ueno NT, Reuben JM, Cristofanilli M. Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. International journal of cancer. 2011 Jul;129(2):417-23.   PMCID: not NIH funded
Reuben JM, Lee BN, Gao H, Cohen EN, Mego M, Giordano A, Wang XM, Lodhi A, Krishnamurthy S, Hortobagyi GN, Cristofanilli M, Lucci A, Woodward WA. Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44(+)CD24(lo) cancer stem cell phenotype. European Journal of Cancer. 2011 Jul;47(10):1527-36.   PMCID: PMC3116032
Salama JK, Saba N, Quon H, Garg MK, Lawson J, McDonald MW, Ridge JA, Smith RV, Yeung AR, Yom SS, Beitler JJ, Expert Panel Radiation O. ACR appropriateness criteria (R) adjuvant therapy for resected squamous cell carcinoma of the head and neck. Oral Oncology. 2011 Jul;47(7):554-9.   PMCID: not NIH funded
Showalter TN, Winter KA, Berger AC, Regine WF, Abrams RA, Safran H, Hoffman JP, Benson AB, MacDonald JS, Willett CG. THE INFLUENCE OF TOTAL NODES EXAMINED, NUMBER OF POSITIVE NODES, AND LYMPH NODE RATIO ON SURVIVAL AFTER SURGICAL RESECTION AND ADJUVANT CHEMORADIATION FOR PANCREATIC CANCER: A SECONDARY ANALYSIS OF RTOG 9704. International Journal of Radiation Oncology Biology Physics. 2011 Dec;81(5):1328-35.   PMCID: PMC3038247
Swaby RF, Cristofanilli M. Circulating tumor cells in breast cancer: A tool whose time has come of age. BMC Medicine. 2011 Apr;9:43.   PMCID: PMC3107794
Wong YN, Ottesen RA, Hughes ME, Niland JC, Theriault R, Edge SB, Blayney D, Weeks JC. Continued Use of Trastuzumab Beyond Disease Progression in the National Comprehensive Cancer Network: Should We Practice Ahead of the Evidence?. The oncologist. 2011 Jan;16(5):559-65.   PMCID: PMC3228199
Zhang H, Kouadio A, Cartledge D, Godwin AK. Role of gamma-synuclein in microtubule regulation. Experimental Cell Research. 2011 Jun;317(10):1330-9.   PMCID: *
Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Das P, Denlinger C, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn M, Meredith K, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Washington MK, Willett C, Wood DE, Wright CD, Yang G, Nccn Gastric Canc Panel Members. Gastric Cancer Clinical Practice Guidelines in Oncology (TM). Journal of the National Comprehensive Cancer Network. 2010 Apr;8(4):378-409.   PMCID: not NIH funded
Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, Cimprich B, Cleeland C, Eisenberger MA, Escalante CP, Jacobsen PB, Kaldor P, Ligibel JA, Murphy BA, O'Connor T, Pirl WF, Rodler E, Rugo HS, Thomas J, Wagner LI. Cancer-Related Fatigue. Journal of the National Comprehensive Cancer Network. 2010 Aug;8(8):904-31.   PMCID: not NIH funded
Biermann JS, Adkins DR, Benjamin RS, Brigman B, Chow W, Conrad EU, Frassica DA, Frassica FJ, George S, Hande KR, Hornicek FJ, Letson GD, Mayerson J, McGarry SV, McGrath B, Morris CD, O'Donnell RJ, Randall RL, Santana VM, Satcher RL, Siegel HJ, Somaiah N, Yasko AW. Bone Cancer. Journal of the National Comprehensive Cancer Network. 2010 Jun;8(6):688-712.   PMCID: not NIH funded
Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu JM, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncology. 2010 Jan;11(1):21-8.   PMCID: not NIH funded
Demetri GD, Antonia S, Benjamin RS, Bui MM, Casper ES, Conrad EU, DeLaney TF, Ganjoo KN, Heslin MJ, Hutchinson RJ, Kane JM, Letson GD, McGarry SV, O'Donnell RJ, Paz IB, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schupak KD, Schwartz HS, Thornton K, von Mehren M, Wayne J. Soft Tissue Sarcoma. Journal of the National Comprehensive Cancer Network. 2010 Jun;8(6):630-74.   PMCID: not NIH funded
Deng S, Yang XJ, Lassus H, Liang S, Kaur S, Ye QR, Li CS, Wang LP, Roby KF, Orsulic S, Connolly DC, Zhang YC, Montone K, Butzow R, Coukos G, Zhang L. Distinct Expression Levels and Patterns of Stem Cell Marker, Aldehyde Dehydrogenase Isoform 1 (ALDH1), in Human Epithelial Cancers. Plos One. 2010 Apr;5(4):E10277.   PMCID: PMCID: PMC2858084
Gopal RS, Dubey S, Rosenzweig KE, Chang JY, Decker R, Gewanter RM, Kong FM, Lally BE, Langer CJ, Lee HK, Movsas B. ACR APPROPRIATENESS CRITERIA (R) ON INDUCTION AND ADJUVANT THERAPY FOR STAGE N2 NON-SMALL-CELL LUNG CANCER: EXPERT PANEL ON RADIATION ONCOLOGY-LUNG. International Journal of Radiation Oncology Biology Physics. 2010 Nov;78(4):969-74.   PMCID: not NIH funded
Greer BE, Koh WJ, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Copeland L, Crispens MA, DuPont N, Eifel PJ, Gaffney DK, Huh WK, Kapp DS, Lurain JR, Martin L, Morgan MA, Morgan RJ, Mutch D, Remmenga SW, Reynolds RK, Small W, Teng N, Valea FA. Cervical Cancer. Journal of the National Comprehensive Cancer Network. 2010 Dec;8(12):1388-416.   PMCID: not NIH funded
Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD, Gadgeel SM. A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research. 2010 Apr;16(8):2450-7.   PMCID: not NIH funded
Hoffman JP. Status of Neoadjuvant Therapy for Resectable Pancreatic Cancer. Surgical Oncology Clinics of North America. 2010 Apr;19(2):411-+.   PMCID: not NIH funded
Mego M, Mani SA, Cristofanilli M. Molecular mechanisms of metastasis in breast cancer-clinical applications. Nature Reviews Clinical Oncology. 2010 Dec;7(12):693-701.
Movsas B, Langer CJ, Ross HJ, Wang LH, Jotte RM, Feigenberg S, Xu F, Huang CH, Monberg MJ, Obasaju CK. Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B Unresectable Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 2010 May;5(5):673-9.   PMCID: not NIH funded
Rose PG, Tian CQ, Bookman MA. Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology. 2010 May;117(2):324-9.   PMCID: NIH funded - needs PMCID
Rusthoven KE, Feigenberg SJ, Raben D, Kane M, Song JI, Nicolaou N, Mehra R, Burtness B, Ridge J, Swing R, Lango M, Cohen R, Jimeno A, Chen CH. INITIAL RESULTS OF A PHASE I DOSE-ESCALATION TRIAL OF CONCURRENT AND MAINTENANCE ERLOTINIB AND REIRRADIATION FOR RECURRENT AND NEW PRIMARY HEAD-AND-NECK CANCER. International Journal of Radiation Oncology Biology Physics. 2010 Nov;78(4):1020-5.   PMCID: not NIH funded
Wong YN, Hamilton O, Egleston B, Salador K, Murphy C, Meropol NJ. Understanding How Out-of-Pocket Expenses, Treatment Value, and Patient Characteristics Influence Treatment Choices. The oncologist. 2010 Jan;15(6):566-76.   PMCID: PMCID: PMC2892556 [Available on 2011/1/1]
Burtness B, Gibson M, Egleston B, Mehra R, Thomas L, Sipples R, Quintanilla M, Lacy J, Watkins S, Murren JR, Forastiere AA. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Annals of Oncology. 2009 Jul;20(7):1242-8.   PMCID: PMC2699385
Earle CC, Weiser MR, Ter Veer A, Skibber JM, Wilson J, Rajput A, Wong YN, Benson AB, Shibata S, Romanus D, Niland J, Schrag D. Effect of Lymph Node Retrieval Rates on the Utilization of Adjuvant Chemotherapy in Stage II Colon Cancer. Journal of surgical oncology. 2009 Dec;100(7):525-8.   PMCID: not NIH funded
Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. Colon Cancer. Journal of the National Comprehensive Cancer Network. 2009 Sep;7(8):778-831.   PMCID: no NIH - Practice Guideline
Gold HT, Hall MJ, Blinder V, Schackman BR. Cost Effectiveness of Pharmacogenetic Testing for Uridine Diphosphate Glucuronosyltransferase 1A1 Before Irinotecan Administration for Metastatic Colorectal Cancer. Cancer. 2009 Sep;115(17):3858-67.   PMCID: PMC2853177
Rosenthal DI, Harris J, Forastiere AA, Weber RS, Ridge JA, Myers JN, Garden AS, Kuettel MR, Sidhu K, Schultz CJ, Trotti A, Ang KK. Early Postoperative Paclitaxel Followed by Concurrent Paclitaxel and Cisplatin With Radiation Therapy for Patients With Resected High-Risk Head and Neck Squamous Cell Carcinoma: Report of the Phase II Trial RTOG 0024. Journal of Clinical Oncology. 2009 Oct;27(28):4727-32.   PMCID: PMC2754914
Perry JR, Rizek P, Cashman R, Morrison M, Morrison T. Temozolomide Rechallenge in Recurrent Malignant Glioma by Using a Continuous Temozolomide Schedule The "Rescue" Approach. Cancer. 2008 Oct;113(8):2152-7.
Suh WW, Blackstock AW, Herman J, Konski AA, Mohiuddin M, Poggi MM, Regine WF, Cosman BC, Saltz L, Johnstone PA. ACR appropriateness criteria on resectable rectal cancer. International Journal of Radiation Oncology Biology Physics. 2008 Apr;70(5):1427-30.
Devlin JG, Langer CJ. Salvage therapy with vinorelbine in advanced non-small-cell lung cancer: A retrospective review of the Fox Chase Cancer Center experience and a review of the literature. Clinical lung cancer. 2007 Mar;8(5):319-26.
Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB, Blanke CD, Diasio RB, Grothey A, Lenz HJ, Meropol NJ, Ramanathan RK, Becerra CH, Wickham R, Armstrong D, Viele C. The continuum of care: A paradigm for the management of metastatic colorectal cancer. The oncologist. 2007 Jan;12(1):38-50.
Hensley H, Quinn BA, Wolf RL, Litwin SL, Mobuchi S, Williams SJ, Williams C, Hamilton TC, Connolly DC. Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer. Cancer Biology & Therapy. 2007 Nov;6(11):1717-25.
Hess LM, Barakat R, Tian C, Ozols RF, Alberts DS. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology. 2007 Nov;107(2):260-5.
Barsevick AM, Dudley WN, Beck SL. Cancer-related fatigue, depressive symptoms, and functional status. Nursing research. 2006 Sep;55(5):366-72.
Barsevick AM, Whitmer K, Nail LM, Beck SL, Dudley WN. Symptom cluster research: Conceptual, design, measurement, and analysis issues. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT. 2006 Jan;31(1):85-95.
Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, Rose GS, Spirtos NM. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study. GYNECOLOGIC ONCOLOGY. 2006 Sep;102(3):432-9.
Bookman MA, McMeekin DS, Fracasso PM. Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: A phase I study of the Gynecologic Oncology Group. Gynecologic Oncology. 2006 Nov;103(2):473-8.
Chang JY, Moughan J, Johnstone DW, Komaki R, Goldberg M, Langer CJ, Beadle BM, Owen J, Movsas B. Surgical patterns of care in operable lung carcinoma treated with radiation. JOURNAL OF THORACIC ONCOLOGY. 2006 Jul;1(6):526-31.
Henry LR, Goldberg M, Scott W, Konski A, Meropol NJ, Freedman G, Weiner LM, Watts P, Beard M, McLaughlin S, Cheng JD. Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: A phase II report. ANNALS OF SURGICAL ONCOLOGY. 2006 Feb;13(2):214-20.
Langer CJ. Treatment of stage I-III non-small-cell lung cancer in the elderly - The Gridelli/Maione/Rossi article reviewed. ONCOLOGY-NEW YORK. 2006 Apr;20(4):385-+.
Masters GA, Li SG, Dowlati A, Madajewicz S, Langer C, Schiller J, Johnson D. A phase II trial of carboplatin and gemcitabine with exisulind (IND #65,056) in patients with advanced non-small cell lung cancer: An Eastern Cooperative Oncology Group Study (E1501). JOURNAL OF THORACIC ONCOLOGY. 2006 Sep;1(7):673-8.
Movsas B, Scott C, Watkins-Bruner D. Pretreatment factors significantly influence quality of life in cancer patients: A radiation therapy oncology group (RTOG) analysis. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2006 Jul;65(3):830-5.
Ngo L, Nei M, Glass J. Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma. EPILEPSIA. 2006 Jul;47(7):1237-8.
Ozols RF, Bookman MA, Young RC, Du Bois A, Pfisterer J, Reuss A. Intraperitoneal cisplatin therapy in ovarian cancer: Comparison with standard intravenous carboplatin and paclitaxel. GYNECOLOGIC ONCOLOGY. 2006 Oct;103(1):1-6.
Wakelee HA, Wang W, Schiller JH, Langer CJ, Sandler AB, Belani CP, Johnson DH, Eastern Cooperative Oncology Grp. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. JOURNAL OF THORACIC ONCOLOGY. 2006 Jun;1(5):441-6.
Ang KK, Harris J, Garden AS, Trotti A, Jones CU, Carrascosa L, Cheng JD, Spencer SS, Forastiere A, Weber RS. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation therapy oncology group phase II trial 99-14. Journal of Clinical Oncology. 2005 May;23(13):3008-15.
Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H, Goldberg M. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. Journal of Clinical Oncology. 2005 Jul;23(19):4330-7.
Greer BE, Bundy BN, Ozols RF, Fowler JA, Clarke-Pearson D, Burger RA, Mannel R, DeGeest K, Hartenbach EM, Baergen RN, Copeland LJ. Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: A non-randomized comparison using an explanatory analysis: A Gynecologic Oncology Group study. Gynecologic Oncology. 2005 Oct;99(1):71-9.
Henry LR, Sigurdson E, Arciero CA, Watson JC. A disappearing hepatic infusion pump. Journal of Gastrointestinal Surgery. 2005 Jul;9(6):878-9.
Konski A, Hoffman J, Sigurdson E, Haluszka O, Engstrom P, Cheng JD, Cohen SJ, Watson JC, Eisenberg D, McGarrity E, Freedman G, Meropol NJ. Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experience. SEMINARS IN ONCOLOGY. 2005 Jan;32(6):S63-S67.
Machtay M, Hsu C, Komaki R, Sause WT, Swann RS, Langer CJ, Byhardt RW, Curran WJ. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: Analysis of the Radiation Therapy Oncology Group (RTOG) experience. International Journal of Radiation Oncology Biology Physics. 2005 Nov;63(3):667-71.
Miller DS, Blessing JA, Waggoner S, Schilder J, Sorosky J, Bloss J, Schilder R. Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: A Gynecologic Oncology Group Study. Gynecologic Oncology. 2005 Jan;96(1):67-71.
Mulcahy MF, Loehrer PJ, Meropol NJ, Rademaker AW, Benson AB. A phase I study of docetaxel, cisplatin, 5-fluorouracil and leucovorin. Oncology. 2005 Jan;68 (4-6):479-84.
Rogatko A, Babb JS, Tighiouart M, Khuri FR, Hudes G. New paradigm in dose-finding trials: Patient-specific dosing and beyond phase I. Clinical Cancer Research. 2005 Aug;11(15):5342-6.
Siegelmann-Danieli N, Ben-Izhack O, Hanlon A, Ridge JA, Stein ME, Khandelwal V, Langer CJ. P53 alteration in oral tongue cancer is not significantly associated with age at diagnosis or tobacco exposure. Tumori. 2005 Jul;91(4):346-50.
Somer RA, Langer CJ. Response to temozolomide in second-line treatment of recurrent nonsmall cell lung carcinoma: Case report. Cancer Investigation. 2005 Mar;23(2):134-7.
Swaby RF, Bhalla KN. Importance of rational pre-clinical development - Gemcitabine comes of age. CANCER BIOLOGY & THERAPY. 2005 Aug;4(8):872-3.
Werner-Wasik M, Langer C, Movsas B. Amifostine in chemoradiation therapy for non-small cell lung cancer: Review of experience and design of a phase II trial assessing subcutaneous and intravenous bolus administration. Seminars in Oncology. 2005 Apr 03;32(2):S105-S108.
Anderson PR, Hanlon AL, McNeeley SW, Freedman GM. Low complication rates are achievable after postmastectomy breast reconstruction and radiation therapy. International Journal of Radiation Oncology Biology Physics. 2004 Jul;59(4):1080-7.
Ansell SM, Schilder RJ, Pieslor PC, Gordon LI, Emmanouilides C, Vo K, Czuczman MS, Witzig TE, Theuer C, Molina A. Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: A review of the literature. Clinical Lymphoma. 2004 Dec;5(3):202-4.
Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, Sung J, Raut M, Oster G. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology. 2004 Jan;67 (5-6):390-6.
Gervasoni JE, Hindenburg AA, Vezeridis MP, Schulze S, Wanebo HJ, Mehta S. An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and daunorubicin by induction of both necrosis and apoptosis. Anticancer research. 2004 Sep;24(5A):2617-26.
Ibrahim D, Smith MR, Varterasian M, Karanes C, Millenson M, Yeslow G, Pemberton P, Lai P, Abrams J, Al-Katib A. Phase II study of PEND chemotherapy in patients with refractory/relapsed Hodgkin lymphoma. Leukemia & lymphoma. 2004 Oct;45(10):2079-84.
Konski A. Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer. International Journal of Radiation Oncology Biology Physics. 2004 Dec;60(5):1373-8.
Langer C, Lilenbaum R. Patients with non-small cell lung cancer and poor performance status: A significant population with limited data. Seminars in Oncology. 2004 Dec 11;31(6):1-2.
Meyers MO, Meszoely IM, Hoffman JP, Watson JC, Ross E, Eisenberg BL. Is reporting of recurrence data important in pancreatic cancer?. Annals of Surgical Oncology. 2004 Mar;11(3):304-9.
Morris GJ, Millenson MM, Padavic-Shaller K, Wang H, Rogatko A, Clyde J, Boyd RL, Yeslow G, Halbherr T, Schilder RJ, Smith MR. Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphorna. Haematologica. 2004 Dec;89(12):1484-91.
Ozols RF. NICE guidelines for ovarian cancer: Recommendations versus standard care. Cancer Investigation. 2004 Jan;22 (5):815-7.
Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, Bukowski R, Haas N, Lockbaum P, Li YP, Arends R, Foon KA, Schwab G, Dutcher J. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. Journal of Clinical Oncology. 2004 Aug;22(15):3003-15.
Garcia AA, Bookman MA, Rodriguez-Rodriguez L, Mutch DG, Look KY. Phase I escalation of gemcitabine combined with protracted oral etoposide in gynecologic malignancies - A Gynecologic Oncology Group study. Investigational New Drugs. 2002 Nov;20(4):383-7.
Komaki R, Seiferheld W, Ettinger D, Lee JS, Movsas B, Sause W. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: Long-term follow-up of RTOG 92-04. International Journal of Radiation Oncology Biology Physics. 2002 Jul;53(3):548-57.
Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-Lopez AJ, White CA. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood. 2002 Jun 15;99(12):4336-42.
Cheng JD, Hitt J, Koczwara B, Schulman KA, Burnett CB, Gaskin DJ, Rowland JH, Meropol NJ. Impact of quality of life on patient expectations regarding phase I clinical trials. Journal of Clinical Oncology. 2000 Jan;18(2):421-8.
Coia LR, Minsky BD, Berkey BA, John MJ, Haller D, Landry J, Pisansky TM, Willett CG, Hoffman JP, Owen JB, Hanks GE. Outcome of patients receiving radiation for cancer of the esophagus: Results of the 1992-1994 patterns of care study. Journal of Clinical Oncology. 2000 Feb;18(3):455-62.
Glisson B, Scott C, Komaki R, Movsas B, Wagner H. Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: Results of radiation therapy oncology group trial 93-12. Journal of Clinical Oncology. 2000 Aug;18(16):2990-5.
Joseph P, Long DJ, Klein-Szanto AJ, Jaiswal AK. Role of NAD(P)H : quinone oxidoreductase 1 (DT diaphorase) in protection against quinone toxicity. Biochemical pharmacology. 2000 Jul 15;60(2):207-14.
McGuire WP, Blessing JA, Bookman MA, Lentz SS, Dunton CJ. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Journal of Clinical Oncology. 2000 Mar;18(5):1062-7.
Meek PM, Nail LM, Barsevick A, Schwartz AL, Stephen S, Whitmer K, Beck SL, Jones LS, Walker BL. Psychometric testing of fatigue instruments for use with cancer patients. Nursing research. 2000 Jul;49(4):181-90.
Mock V, Atkinson A, Barsevick A, Cella D, Cimprich B, Cleeland C, Donnelly J, Eisenberger MA, Escalante C, Hinds P, Jacobsen PB, Kaldor P, Knight SJ, Peterman A, Piper BF, Rugo H, Sabbatini P, Stahl C. NCCN Practice Guidelines for cancer-related fatigue. Oncology-New York. 2000 Nov;14(11A):151-61.
O'Donnell MR, Appelbaum FR, Baer MR, Carabasi MH, Coutre SE, Erba HP, Estey E, Glenn MJ, Kraut EH, Maslak P, Millenson M, Miller CB, Saba HI, Stone R, Tallman MS. NCCN Practice Guidelines for acute myelogenous leukemia. Oncology-New York. 2000 Nov;14(11A):53-61.
Coia LR, Gunderson LL, Haller D, Hoffman J, Mohiuddin M, Tepper JE, Berkey B, Owen JB, Hanks GE. Outcomes of patients receiving radiation for carcinoma of the rectum - Results of the 1988-1989 patterns of care study. Cancer. 1999 Nov 15;86(10):1952-8.
Eifel PJ, Moughan J, Owen J, Katz A, Mahon I, Hanks GE. Patterns of radiotherapy practice for patients with squamous carcinoma of the uterine cervix: Patterns of care study. International Journal of Radiation Oncology Biology Physics. 1999 Jan 15;43(2):351-8.
Epstein BE, Pajak TF, Haulk TL, Herpst JM, Order SE, Abrams RA. Metastatic nonresectable fibrolamellar hepatoma - Prognostic features and natural history. American Journal of Clinical Oncology-Cancer Clinical Trials. 1999 Feb;22(1):22-8.
Freedman G, Fowble B, Hanlon A, Nicolaou N, Fein D, Hoffman J, Sigurdson E, Boraas M, Goldstein L. Patients with early stage invasive cancer with close or positive margins treated with conservative surgery and radiation have an increased risk of breast recurrence that is delayed by adjuvant systemic therapy. International Journal of Radiation Oncology Biology Physics. 1999 Jul 15;44(5):1005-15.
Langer CJ. Concurrent chemoradiation using paclitaxel and carboplatin in locally advanced non-small cell lung cancer. Seminars in Radiation Oncology. 1999 Apr;9(2):108-16.
Langer CJ, Gandara DR, Calvert P, Edelman MJ, Ozols RF. Gemcitabine and carboplatin in combination: An update of phase I and phase II studies in non-small cell lung cancer. Seminars in Oncology. 1999 Feb;26(1):12-8.
Meropol NJ, Rustum YM, Creaven PJ, Blumenson LE, Frank C. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: A potential role for growth factor as mucosal protectant. Cancer Investigation. 1999 Jan;17(1):1-9.
Miknyoczki SJ, Chang H, Klein-Szanto A, Dionne CA, Ruggeri BA. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma. Clinical Cancer Research. 1999 Aug;5(8):2205-12.
Ozols R. Treatment of gynecologic cancer: The US experience. Tumori. 1999 May;85(3):S5-S11.
Smitt MC, Stouffer N, Owen JB, Hoppe RT, Hanks GE. Results of the 1988-1989 patterns of care study process survey for Hodgkin's disease. International Journal of Radiation Oncology Biology Physics. 1999 Jan 15;43(2):335-9.
Stevenson JP, DeMaria D, Sludden J, Kaye SB, Paz-Ares L, Grochow LB, McDonald A, Selinger K, Wissel P, O'Dwyer PJ, Twelves C. Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion. Annals of Oncology. 1999 Mar;10(3):339-44.
Tester WJ, Kim KM, Krigel RL, Bonomi PD, Glick JH, Asbury RF, Kirkwood JM, Blum RH, Schiller JH. A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer - An Eastern Cooperative Oncology Group study (PZ586). Lung Cancer. 1999 Sep;25(3):199-206.
Berlin JD, Propert KJ, Trump D, Wilding G, Hudes G, Glick J, Burch P, Keller A, Loehrer P. 5-fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer - An Eastern Cooperative Oncology Group phase II study (E1889). American Journal of Clinical Oncology-Cancer Clinical Trials. 1998 Apr;21(2):171-6.
Bunn PA, Vokes EE, Langer CJ, Schiller JH. An update on North American randomized studies in non-small cell lung cancer. Seminars in Oncology. 1998 Aug;25(4):2-10.
Freedman GM, Fowble BL, Hanlon AL, Myint MA, Hoffman JP, Sigurdson ER, Eisenberg BL, Goldstein LJ, Fein DA. A close or positive margin after mastectomy is not an indication for chest wall irradiation except in women aged fifty or younger. International Journal of Radiation Oncology Biology Physics. 1998 Jun;41(3):599-605.
Langer CJ, Calvert P, Ozols RF. Gemcitabine and carboplatin in combination: Phase I and phase II studies. Seminars in Oncology. 1998 Aug;25(4):51-4.
Langer CJ, Schaebler D, Sauter E, DeMaria D, Johnson C, Reilly DM, Clark J, Leighton J, Aks C, Litwin S, Ridge JA. Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck. 1998 Aug;20(5):385-91.
Morgan AS, Sanderson PE, Borch RF, Tew KD, Niitsu Y, Takayama T, Von Hoff DD, Izbicka E, Mangold G, Paul C, Broberg U, Mannervik B, Henner WD, Kauvar LM. Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase. Cancer Research. 1998 Jun 15;58(12):2568-75.
Movsas B, Hanlon AL, Lanciano R, Scher RM, Weiner LM, Sigurdson ER, Hoffman JP, Eisenberg BL, Cooper HS, Provins S, Coia LR. Phase I dose escalating trial of hyperfractionated pre- operative chemoradiation for locally advanced rectal cancer. International Journal of Radiation Oncology Biology Physics. 1998 Aug;42(1):43-50.
Paz-Ares L, Kunka R, DeMaria D, Cassidy J, Alden M, Beranek P, Kaye S, Littlefield D, Reilly D, Depee S, Wissel P, Twelves C, O'Dwyer P. A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion. British Journal of Cancer. 1998 Nov;78(10):1329-36.
Radjendirane V, Joseph P, Lee YH, Kimura S, Klein-Szanto AJ, Gonzalez FJ, Jaiswal AK. Disruption of the DT diaphorase (NQ01) gene in mice leads to increased menadione toxicity. Journal of Biological Chemistry. 1998 Mar 27;273(13):7382-9.
Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, Fischbach AJ, Curran WJ. Validation and predictive power of radiation therapy oncology group (RTOG) recursive partitioning analysis classes for malignant glioma patients: A report using rtog 90-06. International Journal of Radiation Oncology Biology Physics. 1998 Jan;40(1):51-5.
Witte RS, Ryan LM, Schutt AJ, Carbone PP, Engstrom PF. PALA versus streptozotocin, doxorubicin, and MeCCNU in the treatment of patients with advanced pancreatic carcinoma. Investigational New Drugs. 1998 Jan;16(4):315-8.
Fowble B. Postmastectomy radiation - A modest benefit prevails for high risk patients. Cancer. 1997 Mar 15;79(6):1061-6.
KupczykSubotkowska L, Siahaan TJ, Basile AS, Friedman HS, Higgins PE, Song D, Gallo JM. Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand melphalan conjugate. Journal of medicinal chemistry. 1997 May 23;40(11):1726-30.
Langer CJ. The emerging role of paclitaxel and carboplatin in non-small cell lung carcinoma. In: Updates in Advances in Lung Cancer. 1997. p. 73-90.
Langer CJ, Movsas B, Hudes R, Schol J, Keenan E, Kilpatrick D, Yeung C, Curran W. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: Report of Fox Chase Cancer Center Study 94-001. Seminars in Oncology. 1997 Aug;24(4):89-95.
Lattanzi JP, Coia LR, Scher RM, Engstrom PF, Hoffman JP, Eisenberg BF, Sigursdson ER, Epstein BE, Weiner LM. A prospective phase I/II study of intra-arterial chemotherapy and escalating doses of radiation therapy for surgically unresectable carcinoma confined to the liver. Gi Cancer. 1997 Jan;2(2):111-7.
Ozols RF. Controversies in the management of ovarian cancer. International Journal of Gynecological Cancer. 1997 May;7:27-32.
Ozols RF. Gynecologic oncology group trials in ovarian carcinoma. Seminars in Oncology. 1997 Feb;24(1):S10-S12.
Street JC, Szwergold BS, Matei C, Kappler F, Mahmood U, Brown TR, Koutcher JA. Study of the metabolism of choline and phosphatidylcholine in tumors in vivo using phosphonium-choline. Magnetic Resonance in Medicine. 1997 Nov;38(5):769-75.
Allen SL, Schacter LP, Lichtman SM, Bukowski R, Fusco D, Hensley M, Odwyer P, Mittelman A, Rosenbloom B, Huybensz S. Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma. Investigational New Drugs. 1996 Jan;14(2):213-7.
Cryer JE, Johnson SW, Engelsberg BN, Billings PC. Analysis of HMG protein binding to DNA modified with the anticancer drug cisplatin. Cancer Chemotherapy and Pharmacology. 1996 Jun;38(2):163-8.
Fowble B, Fein DA, Hanlon AL, Eisenberg BL, Hoffman JP, Sigurdson ER, Daly MB, Goldstein LJ. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer. International Journal of Radiation Oncology Biology Physics. 1996 Jul;35(4):669-77.
Gordon LI, Andersen J, Habermann TM, Winter JN, Glick J, Schilder RJ, Cassileth P. Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: Determination of the Maximum-tolerated dose of ProMACE-CytaBOM. Journal of Clinical Oncology. 1996 Apr;14(4):1275-81.
Hoffman JP, Odwyer P, Agarwal P, Salazar H, Ahmad N. Preoperative chemoradiotherapy for localized pancreatic carcinoma - A perspective. Cancer. 1996 Aug;78(3):592-7.
Li CW, Negendank WG, PadavicShaller KA, Odwyer PJ, MurphyBoesch J, Brown TR. Quantitation of 5-fluorouracil catabolism in human liver in vivo by three-dimensional localized F-19 magnetic resonance spectroscopy. Clinical Cancer Research. 1996 Feb;2(2):339-45.
Tester W, Caplan R, Heaney J, Venner P, Whittington R, Byhardt R, True L, Shipley W. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of Radiation Therapy Oncology Group phase II trial 8802. Journal of Clinical Oncology. 1996 Jan;14(1):119-26.
Algan O, Coia LR, Keller SM, Engstrom PF, Weiner LM, Schultheiss TE, Hanks GE. Management of Adenocarcinoma of the Esophagus with Chemoradiation Alone or Chemoradiation Followed by Esophagectomy - Results of Sequential Nonrandomized Phase-Ii Studies. International Journal of Radiation Oncology Biology Physics. 1995 Jun 15;32(3):753-61.
Corn BW, Greven KM, Randall ME, Wolfson AH, Kim RY, Lanciano RM. The Efficacy of Cranial Irradiation in Ovarian-Cancer Metastatic to the Brain - Analysis of 32 Cases. Obstetrics and gynecology. 1995 Dec;86(6):955-9.
Crilley P, Goldstein LJ. Peripheral-Blood Stem-Cell Transplant in Breast-Cancer. Seminars in Oncology. 1995 Jun;22(3):238-49.
Devineni D, Kleinszanto A, Gallo JM. Tissue Distribution of Methotrexate Following Administration as a Solution and as a Magnetic Microsphere Conjugate in Rats Bearing Brain-Tumors. Journal of Neuro-Oncology. 1995 Jan;24(2):143-52.
Fein DA, Lee WR, Lanciano RM, Corn BW, Herbert SH, Hanlon AL, Hoffman JP, Eisenberg BL, Coia LR. Management of Extremity Soft-Tissue Sarcomas with Limb-Sparing Surgery and Postoperative Irradiation - Do Total-Dose, Overall Treatment Time, and the Surgery-Radiotherapy Interval Impact on Local-Control. International Journal of Radiation Oncology Biology Physics. 1995 Jul 15;32(4):969-76.
Kruh GD, Gaughan KT, Godwin A, Chan A. Expression Pattern of Mrp in Human Tissues and Adult Solid Tumor-Cell Lines. Journal of the National Cancer Institute. 1995 Aug 16;87(16):1256-8.
Langer CJ, Leighton JC, Comis RL, Odwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Johnson S, Ozols RF. Paclitaxel by 24- or 1-Hour Infusion in Combination with Carboplatin in Advanced Nonsmall Cell Lung-Cancer - the Fox Chase Cancer Center Experience. Seminars in Oncology. 1995 Aug;22(4):18-29.
Langer CJ, Leighton JC, Comis RL, Odwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Ozols RF. Paclitaxel and Carboplatin in Combination in the Treatment of Advanced Non-Small-Cell Lung-Cancer - a Phase-Ii Toxicity, Response, and Survival Analysis. Journal of Clinical Oncology. 1995 Aug;13(8):1860-70.
Martenson JA, Lipsitz SR, Lefkopoulou M, Engstrom PF, Dayal YY, Cobau CD, Oken MM, Haller DG. Results of Combined-Modality Therapy for Patients with Anal Cancer (E7283) - an Eastern-Cooperative-Oncology-Group-Study. Cancer. 1995 Nov 15;76(10):1731-6.
Miller SM. Monitoring Versus Blunting Styles of Coping with Cancer Influence the Information Patients Want and Need About Their Disease - Implications for Cancer Screening and Management. Cancer. 1995 Jul 15;76(2):167-77.
Scher RM, Kosierowski R, Lusch C, Alexander R, Fox S, Redei I, Green F, Raskay B, Amfoh K, Engstrom PF, Odwyer PJ. Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Investigational New Drugs. 1995 Jan;13(4):347-54.
Sledge GW, Robert N, Sparano JA, Cogleigh M, Goldstein LJ, Neuberg D, Rowinsky E, Baughman C, McCaskillstevens W. Eastern-Cooperative-Oncology-Group Studies of Paclitaxel and Doxorubicin in Advanced Breast-Cancer. Seminars in Oncology. 1995 Jun;22(3):105-8.
Arisawa Y, Sutantoward E, Dalton RR, Sigurdson ER. Short-Term Intrahepatic Fudr Infusion Combined with Bolus Mitomycin-C - Reduced Risk for Developing Drug-Resistance. Journal of surgical oncology. 1994 Jun;56(2):75-80.
Coia L, Hoffman J, Scher R, Weese J, Solin L, Weiner L, Eisenberg B, Paul A, Hanks G. Preoperative Chemoradiation for Adenocarcinoma of the Pancreas and Duodenum. International Journal of Radiation Oncology Biology Physics. 1994 Aug 30;30(1):161-7.
Coia LR. Chemoradiation as Primary Management of Esophageal Cancer. Seminars in Oncology. 1994 Aug;21(4):483-92.
Coia L, Wizenberg M, Hanlon A, Gunderson L, Haller D, Hoffman J, Kline R, Mohiuddin M, Russell A, Tepper J, Owen J, Hanks G. Evaluation and Treatment of Patients Receiving Radiation for Cancer of the Rectum or Sigmoid Colon in the United-States - Results of the 1988-1989 Patterns of Care Study Process Survey. Journal of Clinical Oncology. 1994 May;12(5):954-9.
Joseph P, Sharma MC, Jaiswal AK. Inhibition of Nad(P)H-Quinone Oxidoreductase(1) in Ethacrynic Acid-Resistant Human Colon-Carcinoma Cells. Biochemical pharmacology. 1994 Jun;47(11):2011-5.
Odwyer PJ, Yao KS, Ford P, Godwin AK, Clayton M. Effects of Hypoxia on Detoxicating Enzyme-Activity and Expression in Ht29 Colon Adenocarcinoma Cells. Cancer Research. 1994 Jun 15;54(12):3082-7.
Ozols RF. Carboplatin and Paclitaxel (Taxol(R)) for the Treatment of Advanced Ovarian-Cancer. International Journal of Gynecological Cancer. 1994 Nov;4:13-7.
Sauter ER, Coia LR, Keller SM. Preoperative High-Dose Radiation and Chemotherapy in Adenocarcinoma of the Esophagus and Esophagogastric Junction. Annals of Surgical Oncology. 1994 Jan;1(1):5-10.
Walker F, Roethke SK, Martin G. An Overview of the Rationale, Process, and Nursing Implications of Peripheral-Blood Stem-Cell Transplantation. Cancer nursing. 1994 Apr;17(2):141-8.
Coia LR. The Use of Mitomycin in Esophageal Cancer. Oncology. 1993 Apr;50:53-62.
Curran WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, Nelson DF. Recursive Partitioning Analysis of Prognostic Factors in 3 Radiation-Therapy Oncology Group Malignant Glioma Trials. Journal of the National Cancer Institute. 1993 May 05;85(9):704-10.
Curran WJ, Scott CB, Weinstein AS, Martin LA, Nelson JS, Phillips TL, Murray K, Fischbach AJ, Yakar D, Schwade JG, Corn B, Nelson DF. Survival Comparison of Radiosurgery-Eligible and Radiosurgery- Ineligible Malignant Glioma Patients Treated with Hyperfractionated Radiation-Therapy and Carmustine - a Report of Radiation-Therapy Oncology Group-83-02. Journal of Clinical Oncology. 1993 May;11(5):857-62.
Dabrow MB, Katz H, Odwyer PJ, Afshar C, Glusker JP. Molecular Dimensions and Properties of N- 1-(2-Hydroxyethyl)-2- Nitro-1h-Imidazol-1-Yl Acetamide(Sr2508). Archives of biochemistry and biophysics. 1993 Apr;302(1):259-64.
Komaki R, Pajak TF, Byhardt RW, Emami B, Asbell SO, Roach M, Pedersen JE, Curran WJ, Lattin P, Russell AH, Cox JD. Analysis of Early and Late Deaths on Rtog Nonsmall Cell- Carcinoma of the Lung Trials - Comparison with Calgb-8433. Lung Cancer. 1993 Dec;10(3-4):189-97.
Lanciano RM, Corn BW. Groin Node Irradiation for Vulvar Cancer - Treatment Planning Must Do More Than Scratch the Surface. International Journal of Radiation Oncology Biology Physics. 1993 Nov 15;27(4):987-9.
Lidor YJ, Obriant KC, Xu FJ, Hamilton TC, Ozols RF, Bast RC. Alkylating-Agents and Immunotoxins Exert Synergistic Cytotoxic Activity against Ovarian-Cancer Cells - Mechanism of Action. Journal of Clinical Investigation. 1993 Nov;92(5):2440-7.
Ozols RF, Thigpen JT, Dauplat J, Colombo N, Piccart MJ, Bertelsen K, Levin L, Lund B. Dose Intensity. Annals of Oncology. 1993 Jan;4:49-56.
Perez RP, Hamaguchi K, Tracey PA, Handel LM, Hamilton TC, Godwin AK. Transformation of Rat Ovarian Epithelial and Rat-1 Fibroblast Cell-Lines by Rast24 Does Not Influence Cisplatin Sensitivity. Cancer Research. 1993 Aug 15;53(16):3771-5.
Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, Isaacson S, Rotman M, Asbell SO, Nelson JS, Weinstein AS, Nelson DF. Influence of Location and Extent of Surgical Resection on Survival of Patients with Glioblastoma-Multiforme - Results of 3 Consecutive Radiation-Therapy Oncology Group (Rtog) Clinical- Trials. International Journal of Radiation Oncology Biology Physics. 1993 May 20;26(2):239-44.
Tjulandin SA, Garin AM, Mescheryakov AA, Perevodchikova NI, Gorbunova VA, Sokolov AV, Ljubimova NV, Mironova GT, Molchanov GV, Ozols RF, Hamilton JM. Cisplatin-Etoposide and Carboplatin-Etoposide Induction Chemotherapy for Good-Risk Patients with Germ-Cell Tumors. Annals of Oncology. 1993 Sep;4(8):663-7.
Abe O, Abe R, Asaishi K, Enomoto K, Hattori T, Ino Y, Kikuchi K, Koyama H, Sawa K, Uchino J, Yoshida M, Haybittle JL, Vandevelde T, Vermorken JB, Harvey VJ, Holdaway TM, Kay RG, Mason BH, Forbes JF, Bastert G, Sauerbrei W, Scheurlen H, Schumacher M, Focan C, Lobelle JP, Peek U, Oates GD, Powell J, Durand M, Mauriac L, Gelman RS, Henderson IC, Shapiro CL, Hancock AK, Jackson S, Ragaz J, Korzun A, Wood WC, Yoshimoto M, Baum M, Houghton J, Horgan K, Hughes L, Stewart HJ, Gordon NH, Davis HL, Delozier T, Macelesech J, Rambert P, Andrysek O, Barkmanova J, Owen JR, Howell A, Ribeiro GC, Swindell R, Deoliveira CF, Carstensen B, Palshof T, Johansen H, Korzeniowski S, Skolyszewski J, Andersen KW, Dombernowsky P, Mouridsen HT, Rose C, Corcoran N, Trampisch HJ, Abeloff MD, Carbone PC, Glick J, Gray R, Tormey DC, Buyse M, Mignolet F, Paridaens R, Vandriel OJ, Sylvester RJ, Vandevelde CJ, Vandongen JA, Welvaart K, Scanlon EF, Schurman S, Catalano R, Creech RH, Deschryver A, McGregor K, Yosef HM, McArdle CS, Smith DC, Lara PC, Dent DM, Gudgeon CA, Hacking A, Boccardo F, Izuo M, Bentley A, Doran Z, Fentiman IS, Hayward JL, Rubens RD, Kaufmann M, Jonat W, Vonfournier D, Klefstrom P, Cuzick J, Margreiter R, Asselain B, Pouillard P, Bahi J, Milla A, Sanchiz F, Castiglione M, Cavalli F, Collins J, Gelber RD, Goldhirsch A, Isley MR, Lindtner J, Price KN, Rudenstam CM, Senn HJ, Bliss JM, Chilvers CE, Coombes RC, Marty M, Borovik R, Brufman G, Robinson E, Pannuti F, Takashima S, Yasutomi T, Holm LE, Sonoo H, Yamashita J, Bonte J, Buzdar AU, Smith T, Martin P, Romain S, Ahmann D, Schaid DJ, Hakes T, Norton L, Wittes R, Foroglou P, Lissaios B, Bonadonna G, Delvecchio M, Valagussa P, Veronesi U, Dubois JB, Hayat H, Bianco AR, Lippman ME, Pierce LJ, Simon R, Steinberg SM, Nomura Y, Delahuerta R, Sainz MG, Brown A, Fisher B, Redmond C, Wolmark N, Jackson IM, Palmer MK, Ingle JN, Bengtsson NO, Larsson LG, Lythgoe JP, Kissin M, Blamey RW, Mitchell AK, Robertson JF, Fluckiger H, Nakamura Y, Mathe G, Misset JL, Deshpande N, Dimartino L, Clarke EA, McLaughlin JR, Clark RM, Levine M, Morimoto K, Gundersen S, Hauerjensen M, Host H, Crossley E, Durrant K, Harris A, Clarke M, Collins R, Godwin J, Greaves E, Harwood C, Mead G, Peto R, Wheatley K, Hill C, Lacour J, Laplanche A, Le M, Sarrazin D, Semiglazov V, Brockschmidt J, Cooper MR, Meakin JW, Panzarella T, Pritchard KI, Treurnietdonker AD, Vanputten WL, Easton D, Powles TJ, Gazet JC, Douglas P, Lindtner A, Notter G, Bryant AJ, Ewing GH, Krushen JL, Nissenmeyer R, Forrest AP, McDonald C, Moller TR, Ryden S, Carstensen J, Hatschek T, Soderberg M, Carpenter JT, Crawley J, Green S, Osborne CK, Rutqvist LE, Wallgren A, Brenner H, Hercbergs A, Deboer G, Paterson AH, Naja A, Reid M, Spittle M, Senanayake F, Meier P, Tengrup I, Tennvallnittby L, Caffier H, Bezwoda WR, Holmberg L, Sevelda P, Zielinsky CC, Jakesz R, Buchanan RB, Cross M, Dunn JA, Gillespie, Kelly K, Morrison JM, Litton A, Chlebowski RT. Systemic Treatment of Early Breast-Cancer by Hormonal, Cytotoxic, or Immune Therapy - 133 Randomized Trials Involving 31000 Recurrences and 24000 Deaths among 75000 Women .2. Lancet (London, England). 1992 Jan 11;339(8785):71-85.
Coia L, Krigel R, Hanks G, Comis R, Algazy K, Peters R, McCulloch W, Schien P. A Phase-I Study of Wr-2721 in Combination with Total-Body Irradiation (Tbi) in Patients with Refractory Lymphoid Malignancies. International Journal of Radiation Oncology Biology Physics. 1992 Jan;22(4):791-4.
Comis RL. Developments in Therapy for Extensive-Disease Small-Cell Lung- Cancer. Seminars in Oncology. 1992 Dec;19(6):45-50.
Curran WJ, Herbert SH, Stafford PM, Sandler HM, Rosenthal SA, McKenna WG, Hughes E, Dougherty MJ, Keller S. Should Patients with Postresection Locoregional Recurrence of Lung-Cancer Receive Aggressive Therapy. International Journal of Radiation Oncology Biology Physics. 1992 Jan;24(1):25-30.
Curran WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Nelson DF, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Powlis WD. Does Extent of Surgery Influence Outcome for Astrocytoma with Atypical or Anaplastic Foci (Aaf) - a Report from 3 Radiation- Therapy-Oncology-Group (Rtog) Trials. Journal of Neuro-Oncology. 1992 Mar;12(3):219-27.
Curran WJ, Scott CB, Nelson JS, Weinstein AS, Phillips TL, Murray K, Fischbach AJ, Yakar D, Schwade JG, Powlis WD, Nelson DF. A Randomized Trial of Accelerated Hyperfractionated Radiation- Therapy and Bis-Chlorethyl Nitrosourea for Malignant Glioma - a Preliminary-Report of Radiation-Therapy Oncology Group 83-02. Cancer. 1992 Dec 15;70(12):2909-17.
Fowler WC, Eisenberg BL, Hoffman JP. Hepatic Resection Following Systemic Chemotherapy for Metastatic Colorectal-Carcinoma. Journal of surgical oncology. 1992 Oct;51(2):122-5.
Hanks GE, Peters T, Owen J. Seminoma of the Testis - Long-Term Beneficial and Deleterious Results of Radiation. International Journal of Radiation Oncology Biology Physics. 1992 Jan;24(5):913-9.
Hudes GR, Greenberg R, Krigel RL, Fox S, Scher R, Litwin S, Watts P, Speicher L, Tew K, Comis R. Phase-Ii Study of Estramustine and Vinblastine, 2 Microtubule Inhibitors, in Hormone-Refractory Prostate-Cancer. Journal of Clinical Oncology. 1992 Nov;10(11):1754-61.
Odwyer PJ, Lacreta FP, Schilder R, Nash S, McAleer C, Miller LL, Hudes GR, Ozols RF. Phase-I Trial of Thiotepa in Combination with Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor. Journal of Clinical Oncology. 1992 Aug;10(8):1352-8.
Ozols RF. Advances in the Chemotherapy of Gynecologic Malignancies. Hematological Oncology. 1992 Jan;10(1):43-51.
Pegues D, Axelrod P, McClarren C, Eisenberg BL, Hoffman JP, Ottery FD, Keidan RD, Boraas M, Weese J. Comparison of Infections in Hickman and Implanted Port Catheters in Adult Solid Tumor Patients. Journal of surgical oncology. 1992 Mar;49(3):156-62.
Perez RP, Perez KM, Handel LM, Hamilton TC. Invitro Interactions between Platinum Analogs in Human Ovarian- Carcinoma Cell-Lines. Cancer Chemotherapy and Pharmacology. 1992 Apr;29(6):430-4.
Rosenthal SA, Curran WJ, Herbert SH, Hughes EN, Sandler HM, Stafford PM, McKenna WG. Clinical Stage-Ii Non-Small-Cell Lung-Cancer Treated with Radiation-Therapy Alone - the Significance of Clinically Staged Ipsilateral Hilar Adenopathy (N1 Disease). Cancer. 1992 Nov 15;70(10):2410-7.
Rosenthal SA, Yeung RS, Weese JL, Eisenberg BL, Hoffman JP, Coia LR, Hanks GE. Conservative Management of Extensive Low-Lying Rectal Carcinomas with Transanal Local Excision and Combined Preoperative and Postoperative Radiation-Therapy - a Report of a Phase I-Ii Trial. Cancer. 1992 Jan 15;69(2):335-41.
Schilder RJ, Young RC. Management of Early-Stage Ovarian-Cancer. Hematology-Oncology Clinics of North America. 1992 Aug;6(4):867-77.
Unger EC, Coia L, Gatenby R, Kessler H, Hartz W, Clair M, Broder G. Ct Staging of Esophageal-Carcinoma in Patients Treated by Primary Radiation-Therapy and Chemotherapy. Journal of Computer Assisted Tomography. 1992 Mar;16(2):235-9.
Wiernik PH, Yeap B, Vogl SE, Kaplan BH, Comis RL, Falkson G, Davis TE, Fazzini E, Cheuvart B, Horton J. Hexamethylmelamine and Low or Moderate Dose Cisplatin with or without Pyridoxine for Treatment of Advanced Ovarian-Carcinoma - a Study of the Eastern Cooperative Oncology Group. Cancer Investigation. 1992 Jan;10(1):1-9.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term chemotherapy

chemotherapy cancer radiotherapy therapy carcinoma cisplatin survival surgery trial radiation NCCN Clinical Practice Guidelines paclitaxel radiation-therapy NCCN Guidelines randomized trial expression doxorubicin radiation therapy combination squamous-cell carcinoma management breast-cancer carboplatin positron-emission-tomography phase-ii trial adenocarcinoma phase-ii gemcitabine chemoradiation cyclophosphamide fluorouracil resistance resection 5-fluorouracil randomized-trial phase-iii trial progression irradiation tumors cooperative-oncology-group experience phase-iii Oncology bevacizumab cell lung-cancer disease induction prognostic factors glioblastoma gene toxicity oncology-group topotecan infusion ovarian cancer randomized controlled-trial clinical-trials taxol mutations adjuvant therapy irinotecan system docetaxel randomized growth-factor receptor metastatic breast-cancer treatment high-dose metastatic colony-stimulating factor quality-of-life dexamethasone recurrence colorectal-cancer concurrent curative resection stem-cell transplantation leucovorin peripheral-blood pathology cancer-patients metabolism fatigue adjuvant chemotherapy glioma tumor breast cancer impact esophageal cancer gynecologic-oncology-group transplantation intervention oncology ovarian-cancer metaanalysis neoadjuvant chemoradiotherapy pharmacokinetics locally advanced head non-small-cell lung cancer CHEMOTHERAPY blood tamoxifen advanced colorectal-cancer pancreaticoduodenectomy CARCINOMA cells metastasis plus cetuximab lymphoma lines combination therapy 5- regimen adjuvant postoperative radiotherapy liver metastases term-follow-up mastectomy patient her2 postoperative Chemotherapy progenitor cells apoptosis prognosis term follow-up stage-iii diagnosis neutropenia platinum hepatocellular-carcinoma sarcoma pancreatic cancer breast Male cytoreductive surgery cell-lines acute myeloid-leukemia Neoplasm Staging therapy-oncology-group oxaliplatin bone-marrow transplantation assay overexpression angiogenesis head clinical trial dose intensity etoposide
Last updated on Thursday, June 04, 2020